Decitabine and Cedazuridine Tablets (INQOVI) is an oral medication used for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). As an innovative therapy, its efficacy and effectiveness have attracted significant attention.
What Are the Side Effects of Decitabine and Cedazuridine Tablets (INQOVI)?
Hematological Abnormalities
Myelosuppression: It has the highest incidence, manifested as leukopenia (87%), thrombocytopenia (82%), neutropenia (73%), and anemia (71%). Among these, the proportion of severe grade 3-4 suppression reaches more than 50%.
Infection Risk: 33% of patients develop febrile neutropenia, 21% experience pneumonia, and 14% suffer from sepsis.
Gastrointestinal Reactions.
Constipation (44%).
Diarrhea (37%).
Nausea (40%).
Oral mucositis (41%).
Elevated transaminases (21%).
Systemic Symptoms
Fatigue (55%).
Edema (30%).
Fever (19%).
Weight loss (10%).
Other Common Reactions
Muscle pain (42%).
Arthralgia (40%).
Rash (33%).
Dizziness (33%).
Dyspnea (38%).
Severe Side Effects of Decitabine and Cedazuridine Tablets (INQOVI) That Require Vigilance
Life-Threatening Myelosuppression
May lead to severe infections, bleeding, or even death.
Regular monitoring of complete blood count (CBC) is necessary. Seek medical attention immediately if fever or abnormal bleeding occurs.
Embryo-Fetal Toxicity
Animal studies have shown teratogenicity, so this medication is contraindicated in pregnant women.
Women and men of childbearing age must use effective contraceptive measures during treatment and for 6 months (for women)/3 months (for men) after discontinuing the medication.
Severe Infections
Including sepsis (11% are grade 3-4) and pneumonia (15% are grade 3-4), among which 1% of cases can be fatal.
Hepatic and Renal Injury
Medication should be suspended when serum creatinine ≥ 2 mg/dL or liver enzyme abnormalities occur, and the dosage should be adjusted after recovery.
Precautions for Administration of Decitabine and Cedazuridine Tablets (INQOVI)
Management of Missed Dose or Vomiting
Missed Dose: If a dose is missed, take it as soon as possible within 12 hours; otherwise, skip the missed dose. For each missed dose, extend the treatment cycle by 1 day to complete the 5-dose regimen.
Vomiting: No supplementary dose is needed; continue medication according to the original schedule.
Monitoring Requirements
Before Treatment and Before Each Cycle: A complete blood count (CBC) must be performed to assess bone marrow function.
Hepatic and Renal Monitoring: Regularly check creatinine and liver enzymes, especially in patients with moderately impaired renal function (CLcr 30-59 mL/min).
Drug Interactions
Concomitant Use Prohibited: Avoid concurrent use with drugs metabolized by cytidine deaminase (CDA) (e.g., cytarabine) to prevent increased toxicity.
Special Populations
Lactation: Breastfeeding is prohibited during treatment and within 2 weeks after the last dose.
Elderly Patients: Close monitoring for adverse reactions is required in patients aged 75 years and above.
